Adult-to-adult right-lobe living donor liver transplantation in high model for end-stage liver disease score recipients with hepatitis B virus-related benign liver diseases

Surgery Today

Volumn 43, Issue 9, 2013, Pages 1039-1048

  Jiang, Li ^a   Yan, Lunan ^a   Tan, Yongqiong ^a   Li, Bo ^a   Wen, Tianfu ^a   Yang, Jiayin ^a   Zhao, Jichun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Living donor liver transplantation; Model for end stage liver disease; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; LAMIVUDINE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; BILE DUCT DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATIC ARTERY THROMBOSIS; HEPATITIS B; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LENGTH OF STAY; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PATIENT SAFETY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RECURRENCE RISK; SURVIVAL RATE; TREATMENT OUTCOME; WOUND INFECTION;

ADULT; AGED; END STAGE LIVER DISEASE; FEMALE; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882279118     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0539-z     Document Type: Article

References (24)

1. Kam I. Adult-adult right hepatic lobe living donor liver transplantation for status 2a patients: too little, too late. Liver Transpl. 2002;8:347-9.
2. Testa G, Malagó M, Nadalin S, Hertl M, Lang H, Frilling A, et al. Right-liver living donor transplantation for decompensated end-stage liver disease. Liver Transpl. 2002;8:340-6.
3. Selzner M, Kashfi A, Cattral MS, Selzner N, McGilvray ID, Greig PD, et al. Live donor liver transplantation in high MELD score recipients. Ann Surg. 2010;251:153-7.
4. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601-8.
5. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Successful use of hepatitis B surface antigen-positive liver grafts in recipients with hepatitis B virus-related liver diseases. Liver Transpl. 2011;17:1236-8.
6. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010;10:1861-9.
7. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-96.
8. Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646-57.
9. Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, et al. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl. 2009;15:496-503.
10. Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology. 2008;135:468-76.
11. Lo CM. Complications and long-term outcome of living liver donors: a survey of 1,508 cases in five Asian centers. Transplantation. 2003;75:S12-5.
12. Umeshita K, Fujiwara K, Kiyosawa K, Makuuchi M, Satomi S, Sugimachi K, et al. Operative morbidity of living liver donors in Japan. Lancet. 2003;362:687-90.
13. Akyildiz M, Karasu Z, Arikan C, Kilic M, Zeytunlu M, Gunsar F, et al. Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation. Transplant Proc. 2004;36:1442-4.
14. Freise CE, Gillespie BW, Koffron AJ, Lok AS, Pruett TL, Emond JC, et al. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant. 2008;8:2569-79.
15. Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg. 2005;242:314-23.
16. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl. 2004;10:S74-85.
17. Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Kanazawa A, et al. Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today. 2005;35:216-22.
18. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585-9.
19. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35:1528-35.
20. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34:903-10.
21. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931-7.
22. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006;12:253-8.
23. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology. 2001;120:1828-53.
24. Seehofer D, Rayes N, Berg T, Neuhaus R, Müller AR, Hopf U, et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int. 2000;13:290-6.